METX.F Stock Overview
A preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
ME Therapeutics Holdings Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$2.95 |
52 Week High | CA$2.95 |
52 Week Low | CA$2.95 |
Beta | 0 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 0% |
Recent News & Updates
Recent updates
Shareholder Returns
METX.F | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | -0.8% | -0.2% |
1Y | n/a | 6.0% | 28.8% |
Return vs Industry: Insufficient data to determine how METX.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how METX.F performed against the US Market.
Price Volatility
METX.F volatility | |
---|---|
METX.F Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 10.3% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: METX.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine METX.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | n/a | Salim Dhanji | www.metherapeutics.com |
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. Its lead candidate is a novel antibody drug that targets a key protein involved in the generation of suppressive myeloid cells. The company was incorporated in 2021 and is headquartered in Vancouver, Canada.
ME Therapeutics Holdings Inc. Fundamentals Summary
METX.F fundamental statistics | |
---|---|
Market cap | US$60.44m |
Earnings (TTM) | US$0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs METX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
METX.F income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$0 |
Earnings | US$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did METX.F perform over the long term?
See historical performance and comparison